If the involvement of TNF-α is well known and further attested by the long experience of treatment with TNF inhibitors for both SpA and IBD, clinical trials of anti-IL17A agents in IBD failed to reach the primary endpoint and even appear to have a worsening effect on CD [10]. This evidence concerns the gene IL17A and inflammatory bowel disease.